Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A subset of flavaglines inhibits KRAS nanoclustering and activation.

Journal of cell science - 24 Jun 2020

Yurugi Hajime, Zhuang Yinyin, Siddiqui Farid A, Liang Hong, Rosigkeit Sebastian, Zeng Yongpeng, Abou-Hamdan Hussein, Bockamp Ernesto, Zhou Yong, Abankwa Daniel, Zhao Wenting, Désaubry Laurent, Rajalingam Krishnaraj

Abstract excerpt

The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loading and oncogene activation in cells at nanomolar concentrations. Treatment with rocaglamide, the first discovered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Oncogenes

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Identifiers

PMID: 32501281
DOI: 10.1242/jcs.244111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A subset of flavaglines inhibits KRAS nanoclustering and activation.PMID 32501281Read ↗

Selective Targeting of Ras Mutant Cancers via a New Small MoleculeSemantic proximity Read ↗

Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice.Semantic proximity Read ↗

EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers.Semantic proximity Read ↗

RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.Semantic proximity Read ↗

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRASSemantic proximity Read ↗

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.Semantic proximity Read ↗

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.Semantic proximity Read ↗

Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRASG12C and modulating the KRAS/AKT/ERK signaling axis.Semantic proximity Read ↗

DHHC7 palmitoylates KRAS4A and promotes mutant KRAS-driven pancreatic cancersSemantic proximity Read ↗

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read ↗

Hybrid nanovesicles enhance antitumor efficacy in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.